Angioslide

About Angioslide

Angioslide, established in 2005 by co-founders Eran Hirszowicz and Amos Nahir, operated as a medical device company with a focus on vascular interventions. The company originated from the Naiot Technological Center in Nazareth, Israel, and maintained its headquarters in Netanya, alongside a U.S. office in Minneapolis.

The core of Angioslide's business was the development and commercialization of its PROTEUS™ device family. This technology integrated a standard angioplasty balloon with a proprietary embolic capture mechanism designed to address a common complication during peripheral transluminal angioplasty (PTA) procedures—the release of embolic debris. The PROTEUS device functioned by creating negative pressure through the inward folding of the balloon after inflation, which would suction and trap dislodged particles, preventing them from traveling downstream and causing potential blockages. This provided physicians with a single device to both treat arterial lesions and manage embolic load, aiming to improve procedural safety and outcomes.

The company targeted the peripheral artery disease (PAD) market, which affects millions of individuals. Its client base consisted of hospitals and physicians, specifically interventional radiologists, cardiologists, and vascular surgeons performing angioplasty. The business model centered on the sale of these single-use medical devices. The PROTEUS product line received both FDA 510(k) clearance in the U.S. and CE Mark approval in Europe, allowing for its use in treating arteries of the lower limbs. Angioslide expanded its offerings to include various sizes, such as a 300 mm long device for the superficial femoral artery (SFA) and a low-profile platform for below-the-knee interventions.

Throughout its operational history, Angioslide secured significant funding across multiple rounds from investors including Agate Medical Investments, Triventures, Viola Group, and XT Hi-Tech, raising over $33 million. Notable milestones included receiving FDA clearance for its below-the-knee device in 2012 and completing a $6.3 million financing round in 2013 to expand its U.S. market presence. Despite these achievements and being named one of Israel's most promising startups in 2011, the company is understood to have ceased operations around January 2018.